Clinical Trial Update: SIRT With Tremelimumab and Durvalumab for Resectable HCC [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of selective internal radiation therapy (SIRT) with tremelimumab and durvalumab for resectable hepatocellular …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Jiping Wang, MD, PhD | Conditions: Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma | Phase 1 | Status: RECRUITING